1887

Abstract

Summary

Virus isolated from an outbreak of poliomyelitis in Finland has been examined serologically and at the molecular level. The causative agent was an antigenically unusual strain of type 3 poliovirus, which was unrelated to the strains used to manufacture either live or killed poliovaccines. It is likely that the antigenic properties of the virus played a part in establishing a limited outbreak of poliomyelitis in a vaccinated population.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-67-5-899
1986-05-01
2022-01-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/67/5/JV0670050899.html?itemId=/content/journal/jgv/10.1099/0022-1317-67-5-899&mimeType=html&fmt=ahah

References

  1. Bainton D., Freeman M., Magrath D. I., Sheffield F., Smith J. W. G. 1979; Immunity of children to diphtheria, tetanus and poliomyelitis. British Medical Journal i:854–857
    [Google Scholar]
  2. Crainic R., Couillin P., Blondel B., Cabau N., Bouse A., Horodniceanu F. 1983; Natural variation of poliovirus neutralisation epitopes. Infection and Immunity 41:1217–1225
    [Google Scholar]
  3. Evans D. M., Minor P. D., Schild G. C., Almond J. W. 1983; Critical role of an eight amino acid sequence of VP1 in neutralisation of poliovirus type 3. Nature, London 304:459–462
    [Google Scholar]
  4. European Pharmacopoeia (2nd edn.) 1983; Poliomyelitis vaccine, inactivated. Monograph214
    [Google Scholar]
  5. Ferguson M., Yi-Hua Qi, Minor P. D., Magrath L. D., Spitz M., Schild G. C. 1982; Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3. Lancet ii:122–124
    [Google Scholar]
  6. Ferguson M., Evans D. M. A., Magrath D. I., Minor P. D., Almond J. W., Schild S. C. 1985; Induction of broadly reactive, type specific neutralising antibody to poliovirus type 3 by synthetic peptides. Virology 143:505–515
    [Google Scholar]
  7. Ferguson M., Magrath L. D., Minor P. D., Schild G. C. 1986; WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains. Bulletin of the World Health Organization (in press)
    [Google Scholar]
  8. Lapinlemu K., Stenvik M. 1981; Experiences with polio vaccination and herd immunity in Finland. Developments in Biological Standardization 47:241–246
    [Google Scholar]
  9. Minor P. D. 1980; Comparative biochemical studies of type 3 poliovirus. Journal of Virology 34:73–84
    [Google Scholar]
  10. Minor P. D. 1982; Characterization of strains of type 3 poliovirus by oligonucleotide mapping. Journal of General Virology 59:307–317
    [Google Scholar]
  11. Minor P. D., Schild G. C., Ferguson M., Mackay A., Magrath D. I., John A., Yates P. J., Spitz M. 1982; Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. Journal of General Virology 61:167–176
    [Google Scholar]
  12. Minor P. D., Evans D. M. A., Ferguson M., Schild G. C., Westrop G., Almond J. W. 1985; Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. Journal of General Virology 65:1159–1165
    [Google Scholar]
  13. Nottay B. K., Kew O. M., Hatch M. H., Heyward J. T., Obijeski J. F. 1981; Molecular variation of type 1 vaccine related and wild polioviruses during replication in humans. Virology 108:405–423
    [Google Scholar]
  14. Weekly Epidemiological Record 1985; 2:11
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-67-5-899
Loading
/content/journal/jgv/10.1099/0022-1317-67-5-899
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error